pre-IPO PHARMA

COMPANY OVERVIEW

Integral Molecular is a research-driven biotechnology company creating innovative technologies and a pipeline of therapeutic antibodies for under-exploited membrane protein targets, including GPCRs, ion channels, and transporters. The Company has over a decade of experience in optimizing membrane proteins, enabling the isolation, characterization, and engineering of monoclonal antibodies against otherwise intractable membrane protein targets. Its customers include all of the top pharmaceutical and biotechnology companies.


LOCATION

  • Philadelphia, PA, USA

  • THERAPEUTIC AREAS

  • Immunology
  • Metabolic DIsorders
  • Oncology
  • Pain

  • WEBSITE

    https://www.integralmolecular.com


    CAREER WEBSITE

    https://www.integralmolecular.com/company/careers/


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Oct 20, 2022

    Integral Molecular Launches New Product Lines of Safe Reporter Viruses for Vaccine Development and Pandemic Preparedness


    Sep 15, 2022

    Integral Molecular Licenses Claudin 18.2 Monoclonal Antibodies to CARTEXELL for Oncology Cell Therapies


    Sep 7, 2022

    FDA Accepts Integral Molecular's Letter of Intent (LOI) on Membrane Proteome Array Antibody Specificity Test Into ISTAND Drug Development Tools Pilot Program


    Jun 8, 2022

    Integral Molecular and Optimeos Life Sciences Enter Partnership to Develop mRNA and DNA-Based Gene Therapies Using Molecular Targeting


    May 24, 2022

    Integral Molecular Breaks Ground on New Headquarters, Doubling in Size


    For More Press Releases


    Google Analytics Alternative